112575-11-8

Basic information

• Product Name: (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE
• Synonyms: (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE;2-Bromo-6-(cyanomethyl)pyridine;2-(6-Bromo-2-pyridyl)acetonitrile;2-(6-Bromopyridin-2-yl)
• CAS NO: 112575-11-8
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• Mol File: 112575-11-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 43 °C(Solv: hexane (110-54-3))
• Boiling Point: 305.7 °C at 760 mmHg
• Flash Point: 138.7 °C
• Appearance: /
• Density: 1.575 g/cm³
• Vapor Pressure: 0.000807mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.27±0.12(Predicted)
• CAS DataBase Reference: (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE(112575-11-8)
• EPA Substance Registry System: (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE(112575-11-8)

Safety Data

• Hazardous Substances Data: 112575-11-8(Hazardous Substances Data)

Usage

General Description

"(6-Bromo-pyridin-2-yl)-acetonitrile" is a chemical compound featuring a pyridinyl group, a bromine atom, and an acetonitrile group. It is characterized as a bromide and nitrile, which are functional groups in organic chemistry. Typically, bromides are known for being reactive, while nitriles contain the cyano group (C≡N), which bestows certain chemical properties to the compound. It represents a clear to slightly-yellow liquid form. Commonly used in pharmaceuticals and other synthetic procedures as an intermediate, the chemical (6-BROMO-PYRIDIN-2-YL)-ACETONITRILE is also widely used in chemical and biological research due to its distinctive properties. A six-membered heterocyclic aromatic compound, it contains nitrogen as well which is part of the heteroarene group. The safety, reactivity, and handling of this chemical should be done as per standard chemical handling protocols.

InChI:InChI=1/C7H5BrN2/c8-7-3-1-2-6(10-7)4-5-9/h1-3H,4H2

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 75-05-8 acetonitrile 
• 1279821-19-0 C₁₂H₁₃BrN₂O₂ 
• 773837-37-9 sodium cyanide 
• 83004-10-8 2-bromo-6-bromomethylpyridine 
• 151-50-8 potassium cyanide 
• 557789-12-5 (6-bromopyridin-2-yl)methyl methanesulfonate 

Downstream Products

• 404034-79-3 [2-(6-bromopyridin-2-yl)ethyl]-2-nitrobenzenesulfonamide 
• 404034-80-6 {2-[6-(4-cyanobutyl)pyridin-2-yl]ethyl}-2-nitrobenzenesulfonamide 
• 404034-83-9 N-{2-[6-(5-aminopentyl)pyridin-2-yl]ethyl}-2-nitrobenzenesulfonamide 
• 404034-85-1 4-(2-nitrobenzenesulfonyl)-4,7,17-triazabicyclo[11.3.1]heptadeca-1⁽¹⁷⁾,13,15-triene 
• 404034-84-0 4-(2-nitrobenzenesulfonyl)-4,7,17-triazabicyclo[11.3.1]heptadeca-1⁽¹⁷⁾,13,15-trien-6-one 
• 404034-82-8 2-bromo-N-(5-{6-[2-(2-nitrobenzenesulfonylamino)ethyl]pyridin-2-yl}pentyl) acetamide 
• 404034-86-2 [4-(2-nitrobenzenesulfonyl)-4,7,17-triazabicyclo[11.3.1]heptadeca-1⁽¹⁷⁾,13,15-trien-7-yl]phosphoramidic acid diethyl ester 
• 794522-71-7 2-(6-phenylpyridin-2-yl)acetonitrile 
• 23168-76-5 2-(6-(4-chlorophenyl)pyridine-2-yl)acetonitrile 

Relevant articles and documents

Discovery and Optimization of 2 H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are oncogenic for a number of malignancies, primarily low-grade gliomas and acute myeloid leukemia. We report a medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2H-1λ2-quinoline-2,5(6H)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1). Systematic SAR efforts produced a series of potent pyrid-2-one mIDH1 inhibitors, including the atropisomer (+)-119 (NCATS-SM5637, NSC 791985). In an engineered mIDH1-U87-xenograft mouse model, after a single oral dose of 30 mg/kg, 16 h post dose, between 16 and 48 h, (+)-119 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations, when compared with the approved drug AG-120 (ivosidenib).

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.